Brepocitinib (PF-06700841) is an oral selective dual TYK2/JAK1 inhibitor targeting signaling of multiple cytokines (IFN, IL-6, IL-12, IL-21, IL-22, and IL-23) and based on its cytokine inhibition profile is expected to provide therapeutic benefit in the treatment of plaque psoriasis [6, 7]. Here, TYK2 is linked to psoriasis vulgaris.